A Phase II Study of Radiation Therapy and Vismodegib, for the Treatment of Locally Advanced Basal Cell Carcinoma of the Head and Neck
Phase of Trial: Phase II
Latest Information Update: 12 May 2017
At a glance
- Drugs Vismodegib (Primary)
- Indications Basal cell cancer; Head and neck cancer
- Focus Therapeutic Use
- 03 May 2017 Planned End Date changed from 1 Jan 2018 to 1 Jun 2019.
- 03 May 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jun 2018.
- 10 Jun 2015 Planned End Date changed from 1 Aug 2016 to 1 Jan 2018 as reported by ClinicalTrials.gov record.